KUBÍČKOVÁ, Barbara, Joerg A. SCHENK, Franziska RAMM, Kornelija MARKUSKIENE, Jochen REETZ, Paul DREMSEK, Paulius Lukas TAMOSIUNAS, Laima CEPULYTE, Hoai Anh TRINH, Johannes SCHOLZ, Henry MEMCZAK, Marc HOVESTAEDT, Rene RYLL, Rasa PETRAITYTE-BURNEIKIENE, Victor M. CORMAN, Anika ANDERSSON, Dietmar BECHER, Martin H. GROSCHUP, Stefan KUBICK, Frank SELLRIE, Reimar JOHNE and Rainer G. ULRICH. A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen. Applied Microbiology and Biotechnology. NEW YORK: SPRINGER, 2021, vol. 105, No 12, p. 4957-4973. ISSN 0175-7598. Available from: https://dx.doi.org/10.1007/s00253-021-11342-7.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen
Authors KUBÍČKOVÁ, Barbara (276 Germany, guarantor, belonging to the institution), Joerg A. SCHENK (276 Germany), Franziska RAMM (276 Germany), Kornelija MARKUSKIENE (276 Germany), Jochen REETZ (276 Germany), Paul DREMSEK (276 Germany), Paulius Lukas TAMOSIUNAS (440 Lithuania), Laima CEPULYTE (440 Lithuania), Hoai Anh TRINH (276 Germany), Johannes SCHOLZ (276 Germany), Henry MEMCZAK (276 Germany), Marc HOVESTAEDT (276 Germany), Rene RYLL (276 Germany), Rasa PETRAITYTE-BURNEIKIENE (440 Lithuania), Victor M. CORMAN (276 Germany), Anika ANDERSSON (276 Germany), Dietmar BECHER (276 Germany), Martin H. GROSCHUP (276 Germany), Stefan KUBICK (276 Germany), Frank SELLRIE (276 Germany), Reimar JOHNE (276 Germany) and Rainer G. ULRICH (276 Germany).
Edition Applied Microbiology and Biotechnology, NEW YORK, SPRINGER, 2021, 0175-7598.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30405 Medical biotechnology related ethics
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.560
RIV identification code RIV/00216224:14310/21:00122250
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1007/s00253-021-11342-7
UT WoS 000661794700001
Keywords in English Hepatitis E virus; HEV-1; HEV-2; HEV-3; HEV-4; HEV-7; ratHEV; batHEV; cvHEV; Monoclonal antibody; Cross-reactivity; Cell-free synthesis
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michaela Hylsová, Ph.D., učo 211937. Changed: 4/9/2021 21:09.
Abstract
To generate a hepatitis E virus (HEV) genotype 3 (HEV-3)-specific monoclonal antibody (mAb), the Escherichia coli-expressed carboxy-terminal part of its capsid protein was used to immunise BALB/c mice. The immunisation resulted in the induction of HEV-specific antibodies of high titre. The mAb G117-AA4 of IgG1 isotype was obtained showing a strong reactivity with the homologous E. coli, but also yeast-expressed capsid protein of HEV-3. The mAb strongly cross-reacted with ratHEV capsid protein derivatives produced in both expression systems and weaker with an E. coli-expressed batHEV capsid protein fragment. In addition, the mAb reacted with capsid protein derivatives of genotypes HEV-2 and HEV-4 and common vole hepatitis E virus (cvHEV), produced by the cell-free synthesis in Chinese hamster ovary (CHO) and Spodoptera frugiperda (Sf21) cell lysates. Western blot and line blot reactivity of the mAb with capsid protein derivatives of HEV-1 to HEV-4, cvHEV, ratHEV and batHEV suggested a linear epitope. Use of truncated derivatives of ratHEV capsid protein in ELISA, Western blot, and a Pepscan analysis allowed to map the epitope within a partially surface-exposed region with the amino acid sequence LYTSV. The mAb was also shown to bind to human patient-derived HEV-3 from infected cell culture and to hare HEV-3 and camel HEV-7 capsid proteins from transfected cells by immunofluorescence assay. The novel mAb may serve as a useful tool for further investigations on the pathogenesis of HEV infections and might be used for diagnostic purposes.
PrintDisplayed: 27/7/2024 18:10